These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27668908)

  • 21. Discontinuation of highly active antiretroviral therapy leads to cryptococcal meningitis/choroiditis in an AIDS patient.
    Chronister CL
    Optometry; 2006 Sep; 77(9):438-45. PubMed ID: 16939885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Herpes simplex virus meningitis in 11 patients].
    Binetruy C; Deback C; Roubaud-Baudron C; Agut H; Bricaire F; Bossi P
    Med Mal Infect; 2008 Mar; 38(3):141-5. PubMed ID: 18191515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
    Nachman SA; Stanley K; Yogev R; Pelton S; Wiznia A; Lee S; Mofenson L; Fiscus S; Rathore M; Jimenez E; Borkowsky W; Pitt J; Smith ME; Wells B; McIntosh K
    JAMA; 2000 Jan; 283(4):492-8. PubMed ID: 10659875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Learning from cerebrospinal fluid drug-resistant HIV escape-associated encephalitis: a case report.
    Kang J; Wang Z; Zhou Y; Wang W; Wen Y
    Virol J; 2023 Dec; 20(1):292. PubMed ID: 38072961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
    Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
    Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
    Flynn P; Komar S; Blanche S; Giaquinto C; Noguera-Julian A; Welch S; Lathouwers E; Van de Casteele T; Kakuda TN; Opsomer M
    Pediatr Infect Dis J; 2014 Sep; 33(9):940-5. PubMed ID: 25361024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS?
    Ceballos-Salobreña A; Gaitán-Cepeda LA; Ceballos-Garcia L; Lezama-Del Valle D
    AIDS Patient Care STDS; 2000 Dec; 14(12):627-35. PubMed ID: 11119429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HSV encephalitis in a child with brain stem glioma: a rare complication of therapy. Case report and review of the neurosurgical literature.
    Spacca B; Mallucci C; Riordan A; Appleton R; Thorp N; Pizer B
    Childs Nerv Syst; 2007 Nov; 23(11):1347-50. PubMed ID: 17593375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
    Matheron S; Descamps D; Boué F; Livrozet JM; Lafeuillade A; Aquilina C; Troisvallets D; Goetschel A; Brun-Vezinet F; Mamet JP; Thiaux C;
    Antivir Ther; 2003 Apr; 8(2):163-71. PubMed ID: 12741629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A rare case of HSV-2 encephalitis.
    Oztekin A; Turhan O; Mutlu D; Inan D; Colak D; Yalcin AN
    Infez Med; 2005 Sep; 13(3):192-5. PubMed ID: 16397423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.
    Santos JR; Moltó J; Llibre JM; Pérez N; Capitán ; Miranda C; Clotet B
    HIV Clin Trials; 2009; 10(3):129-34. PubMed ID: 19632951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
    García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
    AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case report: clearance of hepatitis C virus after changing the HAART regimen in a patient infected with hepatitis C virus and the human immunodeficiency virus.
    Endo T; Fujimoto K; Nishio M; Yamamoto S; Obara M; Sato N; Koike T
    J Med Virol; 2009 Jun; 81(6):979-82. PubMed ID: 19382259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing molecular quantification of herpes simplex virus (HSV) in cerebrospinal fluid (CSF) with quantitative structural and functional disease severity in patients with HSV encephalitis (HSVE): Implications for improved therapeutic approaches.
    Ramirez KA; Choudhri AF; Patel A; Lenny NT; Thompson RE; Berkelhammer Greenberg L; Clanton Watson N; Kocak M; DeVincenzo JP
    J Clin Virol; 2018 Oct; 107():29-37. PubMed ID: 30170224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opportunistic infections occurring during highly active antiretroviral treatment.
    Michelet C; Arvieux C; François C; Besnier JM; Rogez JP; Breux JP; Souala F; Allavena C; Raffi F; Garre M; Cartier F
    AIDS; 1998 Oct; 12(14):1815-22. PubMed ID: 9792382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Adult Case of Herpes Simplex Virus-associated Granulomatous Encephalitis.
    Iwai Y; Nishimura K; Fukushima T; Ito T; Watanabe Y; Noro M; Kuwabara S
    Intern Med; 2019 May; 58(10):1491-1494. PubMed ID: 30626834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of Intrathecal Acyclovir Resistant Virus in Herpes Simplex Encephalitis Patients.
    Mitterreiter JG; Titulaer MJ; van Nierop GP; van Kampen JJ; Aron GI; Osterhaus AD; Verjans GM; Ouwendijk WJ
    PLoS One; 2016; 11(5):e0155531. PubMed ID: 27171421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.